Published in Bull World Health Organ on January 01, 1979
Immunization of Human Volunteers With P. Vivax Irradiated Sporozoites (SPZ-Irrad) | NCT01082341
Acquired immunity to malaria. Clin Microbiol Rev (2009) 6.24
Human cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein. Proc Natl Acad Sci U S A (1991) 1.61
Plasmodium berghei sporozoite invasion is blocked in vitro by sporozoite-immobilizing antibodies. Infect Immun (1986) 1.37
The relative contribution of antibodies, CD4+ and CD8+ T cells to sporozoite-induced protection against malaria. Immunology (1993) 1.29
T-cell immunity to peptide epitopes of liver-stage antigen 1 in an area of Papua New Guinea in which malaria is holoendemic. Infect Immun (1997) 1.27
Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2. J Exp Med (1995) 1.23
Cross-protection between attenuated Plasmodium berghei and P. yoelii sporozoites. Parasite Immunol (2007) 1.14
Molecular dissection of the human antibody response to the structural repeat epitope of Plasmodium falciparum sporozoite from a protected donor. Malar J (2004) 1.01
Malaria vaccine development. Clin Microbiol Rev (1994) 1.01
Pre-erythrocytic-stage immune effector mechanisms in Plasmodium spp. infections. Philos Trans R Soc Lond B Biol Sci (1997) 1.00
A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a malaria vaccine candidate. PLoS One (2014) 0.98
Transcription status of vaccine candidate genes of Plasmodium falciparum during the hepatic phase of its life cycle. Parasitol Res (2004) 0.97
Analysis of immune responses against T- and B-cell epitopes from Plasmodium falciparum liver-stage antigen 1 in rodent malaria models and malaria-exposed human subjects in India. Infect Immun (2000) 0.96
Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines. Vaccine (2015) 0.95
Malaria: immunity and prospects for vaccination. West J Med (1981) 0.94
Cellular and humoral immune responses and protection against schistosomes induced by a radiation-attenuated vaccine in chimpanzees. Infect Immun (2001) 0.94
HLA-A2 supertype-restricted cell-mediated immunity by peripheral blood mononuclear cells derived from Malian children with severe or uncomplicated Plasmodium falciparum malaria and healthy controls. Infect Immun (2005) 0.92
Towards an effective malaria vaccine. Arch Dis Child (2007) 0.92
A next-generation genetically attenuated Plasmodium falciparum parasite created by triple gene deletion. Mol Ther (2014) 0.89
Evaluation and optimization of membrane feeding compared to direct feeding as an assay for infectivity. Malar J (2008) 0.87
Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model. PLoS One (2010) 0.87
Reflections on early malaria vaccine studies, the first successful human malaria vaccination, and beyond. Vaccine (2008) 0.85
Malaria vaccine research and development: the role of the WHO MALVAC committee. Malar J (2013) 0.83
Protection of squirrel monkeys against virulent Plasmodium falciparum infections by use of attenuated parasites. Infect Immun (1992) 0.82
Radiation-induced cellular and molecular alterations in asexual intraerythrocytic Plasmodium falciparum. J Infect Dis (2012) 0.82
Discovery of Novel Plasmodium falciparum Pre-Erythrocytic Antigens for Vaccine Development. PLoS One (2015) 0.82
Infection by and protective immune responses against Plasmodium berghei ANKA are not affected in macrophage scavenger receptors A deficient mice. BMC Microbiol (2006) 0.79
Plasmodium vivax Controlled Human Malaria Infection - Progress and Prospects. Trends Parasitol (2016) 0.76
Approaching the target: the path towards an effective malaria vaccine. Mediterr J Hematol Infect Dis (2012) 0.75
Mosquito bite immunization with radiation-attenuated Plasmodium falciparum sporozoites: safety, tolerability, protective efficacy and humoral immunogenicity. Malar J (2016) 0.75
Why not vaccinate against malaria? Br Med J (Clin Res Ed) (1981) 0.75
Immunity to malaria: antigenic variation in chronic infections of Plasmodium knowlesi. Nature (1965) 5.45
Letter: Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. Trans R Soc Trop Med Hyg (1974) 2.22
Drug sensitivity of plasmodium falciparum. An in-vitro microtechnique. Lancet (1978) 5.58
Mefloquine (WR 142,490) in the treatment of human malaria. Science (1975) 5.20
Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc Natl Acad Sci U S A (1990) 5.05
CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc Natl Acad Sci U S A (1988) 4.67
Comparative testing of monoclonal antibodies against Plasmodium falciparum sporozoites for ELISA development. Bull World Health Organ (1987) 4.65
Precipitation of radioactively labeled samples: a semi-automatic multiple-sample processor. Cell Immunol (1972) 3.35
Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV. J Immunol (1986) 3.12
A quinoline methanol (WR 30090) for treatment of acute malaria. Antimicrob Agents Chemother (1973) 2.85
Immunogenicity of synthetic peptides from circumsporozoite protein of Plasmodium falciparum. Science (1985) 2.78
Effects of chloroquine, quinine, and cycloguanil upon the maturation of asexual erythrocytic forms of two strains of Plasmodium falciparum in vitro. Am J Trop Med Hyg (1968) 2.49
B-lymphocyte heterogeneity: development and characterization of an alloantiserum which distinguishes B-lymphocyte differentiation alloantigens. J Exp Med (1977) 2.44
Expression of Plasmodium falciparum circumsporozoite proteins in Escherichia coli for potential use in a human malaria vaccine. Science (1985) 2.44
Letter: Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. Trans R Soc Trop Med Hyg (1974) 2.22
Mistyping ACE heterozygotes. PCR Methods Appl (1993) 2.19
A phenanthrene methanol (WR 33063) for treatment of acute malaria. Antimicrob Agents Chemother (1973) 2.05
A liver-stage-specific antigen of Plasmodium falciparum characterized by gene cloning. Nature (1987) 2.02
Enzymes of purine and pyrimidine metabolism from the human malaria parasite, Plasmodium falciparum. Mol Biochem Parasitol (1982) 1.96
Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein. Science (1991) 1.94
Chloroquine resistance of Plasmodium falciparum in Brazil detected by a simple in vitro method. Bull World Health Organ (1971) 1.93
Inhibitory activity of interferons and interleukin 1 on the development of Plasmodium falciparum in human hepatocyte cultures. J Immunol (1987) 1.89
Characterization of Plasmodium yoelii monoclonal antibodies directed against stage-specific sporozoite antigens. Infect Immun (1987) 1.87
Plasmodium falciparum-infected Anopheles stephensi inconsistently transmit malaria to humans. Am J Trop Med Hyg (1990) 1.85
Point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes and in vitro susceptibility to pyrimethamine and cycloguanil of Plasmodium falciparum isolates from Papua New Guinea. Am J Trop Med Hyg (1996) 1.84
Effect of murine cytomegalovirus on the in vitro responses of T and B cells to mitogens. J Immunol (1976) 1.84
Effect of antibodies to recombinant and synthetic peptides on P. falciparum sporozoites in vitro. Science (1986) 1.81
Immunochromatographic test for malaria diagnosis. Lancet (1996) 1.80
Mixed leukocyte stimulation of normal peripheral leukocytes by autologous lymphoblastoid cells. Science (1970) 1.79
Monoclonal, but not polyclonal, antibodies protect against Plasmodium yoelii sporozoites. J Immunol (1991) 1.78
Plasmodium falciparum: isolation and purification of spontaneously released merozoites by nylon membrane sieves. Exp Parasitol (1982) 1.70
Theta-sensitive cell and erythropoiesis: identification of a defect in W/Wv anemic mice. Science (1977) 1.67
Correction by CSF-1 of defects in the osteopetrotic op/op mouse suggests local, developmental, and humoral requirements for this growth factor. Exp Hematol (1991) 1.62
Complete development of hepatic stages of Plasmodium falciparum in vitro. Science (1985) 1.58
Rapid, large-scale isolation of Plasmodium berghei sporozoites from infected mosquitoes. J Parasitol (1979) 1.57
Malaria in the Australian Defence Force during and after participation in the International Force in East Timor (INTERFET). Med J Aust (2001) 1.55
In vitro stimulation of murine spleen cells using a microculture system and a multiple automated sample harvester. J Immunol Methods (1973) 1.54
Chloroquine-resistant Plasmodium vivax in Papua New Guinea. Trans R Soc Trop Med Hyg (1992) 1.51
An antigenic marker for human thymic lymphocytes. J Immunol (1973) 1.46
Prophylactic activity of mefloquine hydrochloride (WR 142490) in drug-resistant malaria. Bull World Health Organ (1974) 1.45
Sequence of the immunodominant epitope for the surface protein on sporozoites of Plasmodium vivax. Science (1985) 1.44
Inability of malaria vaccine to induce antibodies to a protective epitope within its sequence. Science (1991) 1.43
Human mixed lymphocyte cultures. Evaluation of a microculture technique utilizing the Multiple Automated Sample Harvester (MASH). Clin Exp Immunol (1973) 1.41
Differential effectiveness of complement fixed by IgG and IgM antibodies in the cytolysis of dog kidney tissue culture cells. Immunology (1966) 1.41
A malaria sporozoite surface antigen distinct from the circumsporozoite protein. Bull World Health Organ (1990) 1.40
CSF-1 deficiency in the op/op mouse has differential effects on macrophage populations and differentiation stages. Exp Hematol (1992) 1.37
Specific murine B-cell activation by synthetic single-and double-stranded polynucleotides. J Exp Med (1973) 1.37
Demonstration of a blocking factor in the plasma and spinal fluid of patients with subacute sclerosing panencephalitis. I. Partial characterization. J Exp Med (1974) 1.35
Determination of the drug sensitivity of Plasmodium falciparum. JAMA (1971) 1.33
Gametocytocidal and sporontocidal effects of primaquine and of sulfadiazine with pyrimethamine in a chloroquine-resistant strain of Plasmodium falciparum. Bull World Health Organ (1968) 1.33
Blastogenic response of Toxoplasma-infected mouse spleen cells to T- and B-cell mitogens. Clin Exp Immunol (1975) 1.31
In vitro cultivation of the exoerythrocytic stage of Plasmodium berghei from sporozoites. Science (1981) 1.31
Lymphocyte activation in subacute sclerosing panencephalitis virus and cytomegalovirus infections. In vitro stimulation in response to viral-infected cell lines. J Exp Med (1973) 1.30
Use of microculture plates and the multiple automated sample harvester for in vitro microassay of bacterial toxins. Appl Microbiol (1974) 1.30
Phenoxypropoxybiguanides, prodrugs of DHFR-inhibiting diaminotriazine antimalarials. J Med Chem (2001) 1.29
Plasma and spinal-fluid blocking factor in SSPE. N Engl J Med (1973) 1.23
Plasmodium berghei: immunization of mice against the ANKA strain using the unaltered sporozoite as an antigen. Exp Parasitol (1977) 1.22
Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration. Antimicrob Agents Chemother (2005) 1.21
Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer (1995) 1.19
Bursting atlantal fracture associated with rupture of the transverse ligament. J Bone Joint Surg Am (1970) 1.17
Concentration and separation of erythrocytes infected with Plasmodium falciparum by gradient centrifugation. Bull World Health Organ (1979) 1.17
Human T-cell heterogeneity as delineated with a specific human thymus lymphocyte antiserum. In vitro effects on mitogen response mixed leukocyte culture, cell-mediated lymphocytotoxicity, and lymphokine production. J Clin Invest (1975) 1.16
Solitary bone cyst: treatment with freeze-dried cancellous bone allograft. A study of one hundred seventy-seven cases. J Bone Joint Surg Am (1969) 1.14
Recombinant pseudorabies virus carrying a plasmodium gene: herpesvirus as a new live viral vector for inducing T- and B-cell immunity. Vaccine (1992) 1.14
Establishment of a human fetal cardiac myocyte cell line. In Vitro Cell Dev Biol (1991) 1.13
Synergistic antimalarial activity of dapsone/dihydrofolate reductase inhibitors and the interaction of antifol, antipyrimidine and antipurine combinations against Plasmodium falciparum in vitro. Trans R Soc Trop Med Hyg (1987) 1.13
Surface antigens on Schistosoma mansoni. II. Adsorption of a Forssman-like host antigen by schistosomula. Clin Exp Immunol (1972) 1.12
Identification of the cell population involved in viral-specific cell-mediated cytotoxicity in man: evidence for T cell specificity. J Immunol (1975) 1.12
Increased antimalarial activity of azithromycin during prolonged exposure of Plasmodium falciparum in vitro. Int J Parasitol (1995) 1.11
Induction of major histocompatibility complex antigens within the myocardium of patients with active myocarditis: a nonhistologic marker of myocarditis. J Am Coll Cardiol (1990) 1.11
Protection against malaria induced by irradiated sporozoites. Lancet (1990) 1.10
Evaluation of monoclonal antibodies against Plasmodium vivax sporozoites for ELISA development. Med Vet Entomol (1991) 1.10
Inhibition of SIV/SMM replication in vitro by CD8+ cells from SIV/SMM infected seropositive clinically asymptomatic sooty mangabeys. J Med Primatol (1990) 1.10
In vitro inhibition of the growth of Plasmodium falciparum by Aotus serum. Bull World Health Organ (1979) 1.09
Solitary unicameral bone cyst: treatment with freeze-dried crushed cortical-bone allograft. A review of one hundred and forty-four cases. J Bone Joint Surg Am (1976) 1.08
Comparison of the behaviour of IgG and IgM anti-Forssman antibodies in agglutination, haemolysis and cytolysis. Immunology (1966) 1.07
Evaluation of WR250417 (a proguanil analog) for causal prophylactic activity in the Plasmodium cynomolgi-Macaca mulatta model. Am J Trop Med Hyg (1994) 1.06
The accumulation of lactic acid and its influence on the growth of Plasmodium falciparum in synchronized cultures. In Vitro (1984) 1.04
Cyclosporin immunosuppression as the possible cause of AIDS. N Engl J Med (1983) 1.03
Cloning of Plasmodium yoelii genes expressing three different sporozoite-specific antigens. Microb Pathog (1989) 1.02
Immunological responsiveness of frozen-thawed human lymphocytes. Clin Exp Immunol (1975) 1.02
Polyclonal B-cell activation reveals antibodies against human immunodeficiency virus type 1 (HIV-1) in HIV-1-seronegative individuals. Proc Natl Acad Sci U S A (1990) 1.01
Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. Chemotherapy (1990) 1.01
Antitheta-sensitive regulatory cell (TSRC) and hematopoiesis: regulation of differentiation of transplanted stem cells in W/Wv anemic and normal mice. Blood (1978) 1.00
Morphological effects of 8-aminoquinolines on the exoerythrocytic stages of Plasmodium fallax. Mil Med (1969) 1.00
Host failure in treatment of malaria with sulfalene and pyrimethamine. Ann Intern Med (1975) 1.00
Inhibition of cellular activation of retroviral replication by CD8+ T cells derived from non-human primates. Clin Exp Immunol (1993) 0.99
An in vitro microassay for lymphotoxin using microculture plates and the multiple automated sample harvester. J Immunol Methods (1974) 0.99
Cross-reactivity exists between Mlsa and Mlsd lymphocyte-activating determinants as demonstrated by the negative clonal selection of responder cells in a mixed lymphocyte reaction. Transplant Proc (1979) 0.99
Evaluation of vaccines designed to induce protective cellular immunity against the Plasmodium yoelii circumsporozoite protein: vaccinia, pseudorabies, and Salmonella transformed with circumsporozoite gene. Bull World Health Organ (1990) 0.99
Iron chelators: in vitro inhibitory effect on the liver stage of rodent and human malaria. Am J Trop Med Hyg (1988) 0.99
Quinine disposition during malaria and during induced fever. Clin Pharmacol Ther (1976) 0.99
Chloroquine bioassay using malaria microcultures. Am J Trop Med Hyg (1993) 0.99
Plasmodium yoelii: 17-kDa hepatic and erythrocytic stage protein is the target of an inhibitory monoclonal antibody. Exp Parasitol (1995) 0.99
Characteristics of the 'active rosette test'. I. Technical considerations of the test and comments. J Immunol Methods (1975) 0.99
A quantitative long-term cryobiological study of malarial parasites. Bull World Health Organ (1977) 0.98
Primaquine-induced changes in morphology of exoerythrocytic stages of malaria. Science (1968) 0.98
Gametocytocidal and sporontocidal effects of primaquine upon two strains of Plasmodium falciparum. Mil Med (1969) 0.98
Asymptomatic malaria. Lancet (1970) 0.98